132 related articles for article (PubMed ID: 34864812)
1. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
[TBL] [Abstract][Full Text] [Related]
2.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
[TBL] [Abstract][Full Text] [Related]
5. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
[TBL] [Abstract][Full Text] [Related]
7. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
[TBL] [Abstract][Full Text] [Related]
12. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
13. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
[TBL] [Abstract][Full Text] [Related]
16. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.
Kawase Y; Yamamoto Y; Kameyama R; Kawai N; Kudomi N; Nishiyama Y
Mol Imaging Biol; 2011 Dec; 13(6):1284-9. PubMed ID: 21042866
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
19. The Role Of 18F-FDG PET/CT In Evaluation Of Primary CNS Lymphoma: The Path Less Travelled.
Usman S; Jain A; Riyami KA; Naumani SP; Sukaiti RA; Shamim MS
J Pak Med Assoc; 2023 Aug; 73(8):1744-1746. PubMed ID: 37697779
[TBL] [Abstract][Full Text] [Related]
20. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
